BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35246262)

  • 1. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
    Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
    Silver JA; Bogatchenko M; Pusztaszeri M; Forest VI; Hier MP; Yang JW; Tamilia M; Payne RJ
    J Otolaryngol Head Neck Surg; 2021 Nov; 50(1):63. PubMed ID: 34742355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mutations as a possible factor for determining extent of thyroid surgery.
    Krasner JR; Alyouha N; Pusztaszeri M; Forest VI; Hier MP; Avior G; Payne RJ
    J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):51. PubMed ID: 31623671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased diagnostic sensitivity of palpation-guided thyroid nodule fine-needle aspiration cytology by BRAF V600E-mutation analysis.
    Gimm O; Ivansson K; Beka E; Rossitti HM; Garvin S; Söderkvist P
    J Pathol Clin Res; 2021 Nov; 7(6):556-564. PubMed ID: 34156770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
    Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
    Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
    Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
    Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer.
    Li R; Hao J; Zhu Z; Qiao X; Wang L; Zhou Z
    Biomed Res Int; 2021; 2021():9937742. PubMed ID: 34307677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
    Kwon HJ; Kim EK; Kwak JY
    Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities.
    Gupta S; Ajise O; Dultz L; Wang B; Nonaka D; Ogilvie J; Heller KS; Patel KN
    Arch Otolaryngol Head Neck Surg; 2012 Mar; 138(3):227-33. PubMed ID: 22431868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular evaluation of BRAF gene mutation in thyroid tumors: Significant association with papillary tumors and extra thyroidal extension indicating its role as a biomarker of aggressive disease.
    Ahmad F; Nathani R; Venkat J; Bharda A; Vanere V; Bhatia S; Das BR
    Exp Mol Pathol; 2018 Dec; 105(3):380-386. PubMed ID: 30414980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
    Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules.
    Lee EJ; Song KH; Kim DL; Jang YM; Hwang TS; Kim SK
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):844-50. PubMed ID: 21707687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative RAS mutational analysis is of great value in predicting follicular variant of papillary thyroid carcinoma.
    Hwang TS; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Park KS; Oh SY; Kim SK; Yang JH
    Biomed Res Int; 2015; 2015():697068. PubMed ID: 25648502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.